Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europe and Japan

expertly curated content related to this topic

• evidence & education
  A Randomised, Double Blind, Placebo Controlled Study of Celecoxib, a Selective Cyclooxygenase 2 Inhibitor, on Duoden...

  BACKGROUND : Non-selective cyclooxygenas...
• social & media
  janette lawrence

  Cancer Genetic Counselor at Massachusett...
• evidence & education
  Anal Transitional Zone Neoplasia in Patients with Familial Adenomatous Polyposis After Restorative Proctocolectomy a...

  BACKGROUND : Restorative proctocolectomy...
• evidence & education
  How to Manage a Patient with Multiple Adenomatous Polyps: History and Clinical Features, Genetic Testing, Surveillan...

  Adenomatous polyps are found on screenin...
• evidence & education
  Colon-Specific Delivery of Celecoxib is a Potential Strategy to Improve Toxicological and Pharmacological Properties...

  In general, colon-specific delivery of a...
• social & media
  jaime jessen

  Genetic Counsellor...
• evidence & education
  Colorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention?

  Colorectal cancer (CRC) is presently one...